Effect of Hemodialysis Membranes on Platelet Count

The purpose of this study is to determine if there is a drop in platelet count after hemodialysis. Hemodialysis membranes are known to activate complement and cause a drop in platelets and sometimes in white blood cells. The investigators are going to study one of the membranes which is the Fresenius Optiflux® to check if it causes a drop in platelets.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Thrombocytopenia Blood Platelet Disorders Cytopenia Hematologic Diseases Hemic and Lymphatic Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Island Rehabilitative Service

Staten Island, New York, 10305, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients on Hemodialysis for >=6 months

Exclusion criteria

Hematological Cancers

Myelodysplastic syndromes
Baseline thrombocytopenia
Acute infections (patients on antibiotics)
Patients with Immune thrombocytopenic purpura (ITP)/Thrombotic thrombocytopenic purpura (TTP)
HIV
Liver disease

Treatment and study plan

Primary outcomes

Drop in platelet counts

Time frame: 90 minutes through hemodialysis and immediately after finishing hemodialysis

Sponsors and collaborators

Lead sponsor

Northwell Health

Other

Collaborators

Staten Island University Hospital

Registry information

Important dates

Study start: 2010
Primary completion: 2011
Study completion: 2011
First posted: May 19, 2011
Registry last updated: Feb 7, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed